New patent expiration for Abbvie drug DURYSTA
Annual Drug Patent Expirations for DURYSTA Durysta is a drug marketed by Abbvie and is included in one NDA. It […]
New patent expiration for Abbvie drug DURYSTA Read Post »
Annual Drug Patent Expirations for DURYSTA Durysta is a drug marketed by Abbvie and is included in one NDA. It […]
New patent expiration for Abbvie drug DURYSTA Read Post »
Annual Drug Patent Expirations for FOTIVDA Fotivda is a drug marketed by Aveo Pharms and is included in one NDA.
New patent expiration for Aveo Pharms drug FOTIVDA Read Post »
Annual Drug Patent Expirations for PROBUPHINE Probuphine is a drug marketed by Titan Pharms and is included in one NDA.
New patent expiration for Titan Pharms drug PROBUPHINE Read Post »
Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate
Innovative Strategies in Drug Repurposing Read Post »
SOOLANTRA (ivermectin) Galderma labs lp Patent: 7,550,440 Expiration: Apr 22, 2024 See More … For more information on how DrugPatentWatch
Drug Patent Expirations for the Week of April 21, 2024 Read Post »
Annual Drug Patent Expirations for RAYOS Rayos is a drug marketed by Horizon and is included in one NDA. It
New patent expiration for Horizon drug RAYOS Read Post »
Annual Drug Patent Expirations for ONZETRA+XSAIL Onzetra Xsail is a drug marketed by Currax and is included in one NDA.
New patent expiration for Currax drug ONZETRA XSAIL Read Post »
Annual Drug Patent Expirations for MEGACE+ES Megace Es is a drug marketed by Endo Pharms Inc and is included in
New patent expiration for Endo Pharms drug MEGACE ES Read Post »
Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one
New patent expiration for Galderma Labs drug SOOLANTRA Read Post »
Get fresh news and insights, drug patent expirations & more…